TSRF 786C (Tasrif Pharmaceutical)

TSRF 786C is a bispecific antibody currently in the discovery phase, developed by Tasrif Pharmaceutical for the treatment of various cancers. The molecule is engineered to simultaneously target the Poliovirus receptor (PVR, also known as CD155) on the surface of tumor cells and the CD3 receptor on T cells. By co-engaging these two targets, TSRF 786C acts as a T-cell engager, facilitating the formation of an immunological synapse between cytotoxic T cells and malignant cells. This interaction triggers T-cell activation and the subsequent release of perforins and granzymes, leading to the targeted lysis of PVR-expressing tumor cells. PVR is a known immune checkpoint ligand that is frequently upregulated in solid tumors and hematologic malignancies, making it a strategic target for redirecting immune responses and overcoming tumor-mediated immunosuppression.

Other names

PVR x CD3 bispecific antibodyCD155 x CD3 bispecific antibodyCD-155 x CD3 bispecific antibodyCD 155 x CD3 bispecific antibody